GPT and acute kidney injury: Treatment-related AEs occurred in 2/12 (17%) patients in the aztreonam–avibactam group (frequent bowel movements and chest discomfort in one patient and increased alanine aminotransferase, aspartate aminotransferase, blood alkaline phosphatase and GGT in another patient) and 1/2 (50%) of patients in the BAT group (acute kidney injury); all were mild or moderate in intensity.